EUVIMEDEUVIMED entdecken
Open Access

SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway

Shiwen Zhang, Yansong Cui, Jingwen Chen, Shuaishuai Zhou, Yujiao Zhang, Kuan Li, Yinglong Hou

Acta Biochimica et Biophysica Sinica · 2026

DOI: 10.3724/abbs.2026078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2026. Verfasst von Shiwen Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, China. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesHeart FailurePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaSirtuin 1Sodium-Glucose Transporter 2 InhibitorsStroke VolumeAnimalsSignal TransductionRatsMyocytes, CardiacRats, Inbred DahlMaleSodium-Glucose Transporter 2Mitochondria, Heart

Stichwörter der Autor:innen

HFpEFSGLT2 inhibitorSIRT1/PGC-1α/Mfn-2 pathwaydapagliflozinmitochondrial biosynthesis

Substanzen

dapagliflozinBenzhydryl CompoundsGlucosidesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaSirtuin 1Sodium-Glucose Transporter 2 InhibitorsSirt1 protein, ratPpargc1a protein, ratSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, China.
  • Department of General Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
  • National Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and C…
  • Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
  • Department of Cardiology, Fengxian People's Hospital, Xuzhou 221700, China.
  • Clinical Medical Institute, Xinjiang Medical University, Urumqi 830000, China.

Zitieren

APA

Zhang, S., Cui, Y., Chen, J., Zhou, S., Zhang, Y., Li, K., & Hou, Y. (2026). SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2026078

Vancouver

Zhang S, Cui Y, Chen J, Zhou S, Zhang Y, Li K, et al. SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway. Acta Biochimica et Biophysica Sinica. 2026. doi:10.3724/abbs.2026078

BibTeX
@article{Zhang2026,
  author = {Zhang, Shiwen and Cui, Yansong and Chen, Jingwen and Zhou, Shuaishuai and Zhang, Yujiao and Li, Kuan and Hou, Yinglong},
  title = {SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway},
  journal = {Acta Biochimica et Biophysica Sinica},
  year = {2026},
  doi = {10.3724/abbs.2026078}
}
Kostenlos starten →